Business NewsPR NewsWire • GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

BOSTON, April 14, 2021 /PRNewswire/ -- GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26...

View More : https://www.prnewswire.com:443/news-releases/geneleap-presents-new-preclinical-data-for-hydrogel-encapsulated-tlr9-agoni...
Releted News by prnewswire
Over $ 5 Billion growth expected in Global Space Tourism Market featuring Airbus SE, Bigelow Aerospace LLC, Blue Origin Enterprises LP | 17000+ Technavio Research Report
Le GESDA organise un sommet inaugural en octobre pour les initiatives de diplomatie mondiale basées sur les percées scientifiques émergentes
Strategic Partnerships for Data Platform Modernization
GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021
XNK Therapeutics appoints Dr. Johan Aschan as Chief Medical Officer
Invitation to Kindred Group's presentation of the Interim report for the first quarter 2021
4. Ethnosport-Forum ist beendet